Who we are
Neuroservice Alliance is a global Pre-clinical CRO providing pharmaceutical industries with high-quality services in functional pharmacology based on CNS in vitro and in vivo electrophysiological recordings and behavioral tests.
Our mission is to support CNS and pain research programs in lead selection & optimization, as well as in investigation of Mechanism of Action (MOA) for experimental compounds.
Neuroservice Alliance proposes more than 40 cumulated years of experience in neuropharmacology.
Our CNS electrophysiological & behavioral platforms propose comprehensive and complementary read out to enable reliable decision-making for drug discovery.
Neuroservice Alliance works like a "remote laboratory" with strong scientific interactions, flexible study plans and short turnarounds.
Our commitments
Quality
robust & reproducible data
Speed
large bandwidth and top level platforms
Interaction
expert action all along the study
Flexibility
step by step study plans
Expertise
more than 40 years of experience
Innovation
active R&D programs
Neuroservice News
News
Psychiatric diseases to be understood and treated ONLY by physiological measurements.
Recent epidemiological and genetic studies have pointed out common genes overexpression and/or alteration in psychiatric disorders and for some of these diseases, alteration in brain wiring functions as measured by high-scale brain scan. The first study (published by Dan Geschwind and colleagues from UCLA) reveals that many mentalLire la suite...
Neurosyn, new product from Neuroservice and Synapcell
NEUROSERVICE and SYNAPCELL are very pleased to announce the launch of a joint product, NEUROSYN. This new offer combines a unique in vitro and in vivo approach to document compound’s effects on brain oscillations. NEUROSERVICE has developed over the last 3 years in vitro Multi-Electrode Array measurements toLire la suite...
MEA recordings for LEAD selection and optimization
Over more than 10 years of activity, NEUROSERVICE has demonstrated a unique and top-of-the-art master of the Multi-Electrode Array (MEA) technique to address pharmacological/toxicological questions regarding the Central Nervous System (CNS). MEA recordings for LEAD selection and optimization NEUROSERVICE is very proud to realease a new document illustratingLire la suite...
3rd Annual London Conference
Neuroservice will participate in the 3rd Annual Neuroscience R&D Technologies Conference in London, September 28-29 Conference Speaker Bruno Buisson, Founder & Chief Scientist will give a presentation about Multi-Electrode array (MEA), a breakingthrough platform for functional pharmacology in CNS and Pain discovery programs: LEAD selection and LEAD optimizationLire la suite...
PERAMPANEL activity on Epileptiform Discharges
Most of the anti-epileptic drugs (AED) have been developed empirically and have multiple targets, multiple mechanisms of actions, and sometime multiple side effects. Now let's look at PERAMPANEL. Evolution of anti-epileptic drugs For the past couple of years, pharmaceutical and biotech companies have been trying to develop newLire la suite...
Ketamine effect on neuronal network oscillations
NEUROSERVICE has documented in vitro the (R,S)-ketamine immediate pharmacological activity on neuronal network oscillations in the theta, beta and gamma range frequencies. The very quick anti-depressant effect of (R,S)-ketamine is documented by clinicians for a couple of years. Although there are still intense discussions about the targets andLire la suite...
Neuroservice new publication on pharmacological tools to study NMDA Receptors
MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit MNEMOSYNE has developed new compounds (MPX-004 and MPX-007) that selectively inhibit GluN2A-containing NMDA receptors which are implicated in many CNS disorders. These compound open new pharmacological strategies to address diseases suchLire la suite...
SPECIAL OFFER: High quality LTP data in 2 weeks only
Does your compound modulate LTP? NEW ATTRACTIVE PRICING AND FAST TURN-AROUND We have optimized our internal production process of LTP recording to address cognition and neurodegeneration programs with very attractive prices and fast turn-around. We propose a new offer to evaluate: 1 compound / 1 concentration 1 compound /Lire la suite...
Gamma Oscillations: a new translational biomarker from in vitro to in vivo models
Neuronal rhythms are disordered in schizophrenia, epilepsy, autism, ADHD, Alzheimer’s Disease and Parkinson Disease, among others. Gamma oscillations in the gamma frequency range are thought to be responsible for information transfer and integration between different brain areas. With Neuroservice’s “GOS SET” package based on electrophysiological slice recordings withLire la suite...
New electrophysiological solutions for Safety and Toxicology Profiling
Neuroservice launches two innovative approaches to in vitro electrophysiological recordings in the CNS – now adapted to address current issues in Safety and Toxicology. Solutions presented during the SPS (Safety and Pharmacology Society) Meeting at Washington on October 19-22, 2014. Learn more about the benefits of these ready-to-useLire la suite...
In 2014... We were there!
USA – BIO INTERNATIONAL CONVENTION – San Diego, California – June, 23-26 USA – SPS Annual Meeting (Safety and Pharmacology Society) – Washington – October, 17-22 USA – NEUROSCIENCE 2014 (Society for Neuroscience) – Washington – November, 15-19 JAPAN - 87th Meeting of the Japanese Pharmalogical Society –Lire la suite...
Neuroservice channel
Videos
Neuroservice Blog
Blog
More Americans Than Ever Have Epilepsy
A new Centers for Disease Control and Prevention (CDC) study published in August 2017 reported national and state estimates of the numbers of adultsLire la suite...
What is the precise action of your anti-epileptic drug on neuronal networks and on neurotransmission?
Electrophysiology changes the game     Demonstrating that a potential anti-epilepsy compound has the expected effect requires different stages of analysis, at the neuronalLire la suite...
Cognition studies: your lead compound works in vivo but its mechanism of action (MOA) remains unclear?
    Bruno Buisson, founder, general manager & chief scientist at Neuroservice, explains how electrophysiology can illuminate pharmacological compound profile, providing a clearer understandingLire la suite...
Olesoxime, a first hope for Spinal Muscular Atrophy (SMA) patients
About the author [av_image src='http://www.neuroservice.com/wp-content/uploads/2015/05/Thierry-Bordet-NSblog-2.jpg' attachment='2396' attachment_size='full' align='left' animation='no-animation' link='' target='' styling='' caption='' font_size='' appearance=''][/av_image] Thierry Bordet has more than 15 years of experience leadingLire la suite...
The Evolution of the Contract Research Organization
Jeff is a neuropharmacologist by training with 20 years of experience in the drug discovery divisions of top-tier Pharma organizations.  In the last 4Lire la suite...
Neuroservice blog is launched!
By Bruno Buisson, PhD, Founder, General Manager & Chief Scientist at Neuroservice. It is a great pleasure and honor to release the first articleLire la suite...
Highlighting of the brain for healthcare enlightenment
By Franck DEBARBIEUX, PhD, Scientific Manager of “Intravital Cellular Imaging Technologies” platform (ICI Tech) at CERIMED, Principal Investigator of IMAPATH team at Institut deLire la suite...
Can reverse translational research help discovery of analgesic drugs?
By Alain ESCHALIER, MD, PhD, PharmD, Professor of Pharmacology, Director of the Inserm Unit Neuro-Dol, Faculty of Medicine, University of Auvergne, CHU Clermont-Ferrand; PresidentLire la suite...